Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nexstim OyjFRA:5NX +6.07%69 Gross Margin % is 92.72% as of Jun. 2026, which is 11% above its 10-year median of 83.37. GuruFocus rates FRA:5NX with a GF Score™ of 69/100 and a GF Value™ of €9.65 (Fairly Valued). The stock has 5 warning signs investors should review. Among 804 Medical Devices & Instruments companies, Nexstim Oyj ranks better than 95.9% on this metric.
The historical rank and industry rank for Nexstim Oyj's Gross Margin % or its related term are showing as below:
FRA:5NX'
s Gross Margin % Range Over the Past 10 Years
Min: 23.21 Med: 83.37 Max: 99.95
Current: 88.12
During the past 13 years, the highestGross Margin % of Nexstim Oyj was 99.95%. The lowest was 23.21%. And the median was 83.37%.
FRA:5NX's Gross Margin % is ranked better than 95.9% of 804
companies
in the Medical Devices & Instruments industry
Industry Median: 52.44
vs FRA:5NX: 88.12
Nexstim Oyj had a gross margin of 92.72% for the quarter that ended in Jun. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Nexstim Oyj was 2.20% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Nexstim Oyj had a gross margin of 92.72% for the quarter that ended in Jun. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Nexstim Oyj Gross Margin % Related Terms
Nexstim Oyj Gross Margin % Historical Data
* Premium members only.
The historical data trend for Nexstim Oyj's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5NX vs ABT, SYK, MDT: Gross Margin % Comparison
For the Medical Devices subindustry, Nexstim Oyj's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nexstim Oyj Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nexstim Oyj's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Nexstim Oyj's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Nexstim Oyj (FRA:5NX) has a Gross Margin % of 92.72% as of Jun. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Nexstim Oyj and its competitors. This is 11% above median its historical median of 83.37. Over the past decade, Nexstim Oyj's Gross Margin % has ranged from 23.21 to 99.95. According to the industry distribution chart, Nexstim Oyj ranks #33 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 4.1%.
Is Nexstim Oyj's Gross Margin % too high?
Nexstim Oyj's current Gross Margin % of 92.72% is 11% above median its 10-year median of 83.37. Over the past 10 years, this metric has ranged from a low of 23.21 to a high of 99.95. The Medical Devices & Instruments industry median Gross Margin % is 52.44. Nexstim Oyj's value of 92.72% is 76.8% above this industry median. Based on the distribution chart, Nexstim Oyj ranks #33 out of 804 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Nexstim Oyj has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Nexstim Oyj's Gross Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nexstim Oyj ranks #33 out of 804 companies for Gross Margin %. This places Nexstim Oyj in the top 4% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 52.44. Nexstim Oyj's value of 92.72% is 76.8% above this benchmark. Historically, Nexstim Oyj's own Gross Margin % has ranged from 23.21 to 99.95 over the past decade. While the company's 10-year median is 83.37 vs. the industry median of 52.44, Nexstim Oyj has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 52.44, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nexstim Oyj's current Gross Margin % of 92.72% is 76.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Nexstim Oyj and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 52.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nexstim Oyj's current Gross Margin % is 92.72%, which is 11% above median its own 10-year median of 83.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nexstim Oyj stock overvalued right now?
Based on GuruFocus' analysis, Nexstim Oyj (FRA:5NX) is currently considered Fairly Valued. The stock's GF Value™ is €9.65, compared to a current price of €9.78 — trading 1.3% above its estimated fair value. The current Gross Margin % is 92.72%, which is 11% above median its 10-year median of 83.37 and 76.8% above the Medical Devices & Instruments industry median of 52.44. Nexstim Oyj's overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Nexstim Oyj (FRA:5NX), the current Gross Margin % is 92.72% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nexstim Oyj (FRA:5NX) Overvalued in 2026?
Based on GuruFocus' analysis, Nexstim Oyj stock appears to be overvalued.
The current stock price of €9.78 is trading 1.3% above its estimated GF Value™ of €9.65.
GuruFocus considers Nexstim Oyj to be Fairly Valued.
Key valuation signals for FRA:5NX:
Gross Margin %: 92.72% (11% above median its 10-year median of 83.37)
GF Value™: €9.65 vs. price of €9.78 (1.3% above fair value)
Industry Position: 76.8% above the Medical Devices & Instruments median (#33 of 804)
No single metric tells the full story. See the FRA:5NX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nexstim Oyj is a Finnish medical technology company. It has developed a non-invasive brain-stimulation technology for navigated transcranial magnetic stimulation (nTMS), with sophisticated 3D navigation that provides accurate, personalized targeting of TMS to specific brain areas. The company's diagnostic business focuses on commercializing the NBS System 6, an FDA-cleared, CE-marked navigated TMS system for pre-surgical mapping of the brain's speech and motor cortices. Its therapy business sells the NBS System 6 for the treatment of depressive disorder in the United States, and for the treatment of depression, chronic neuropathic pain, and post-operative rehabilitation of motor deficits of the upper limb, in Europe. Geographically, the firm generates maximum revenue from North America.
69GF Score
Get the complete analysis for FRA:5NX
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5NX has been successfully added to your 
